ClinicaliQ Trial Snapshot
- A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington’s Disease — Recruiting • Phase I • NCT06585449.
- A trial testing whether a new drug (ALN-HTT02) is safe and effective in adults with Huntington's disease.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of single or repeat doses of ALN-HTT02. Conditions: Huntington's Disease Interventions: ALN-HTT02, Placebo Lead Sponsor: Alnylam Pharmaceuticals Planned Enrollment: 66 participants